External Financing for R&D and Capital Investment
First written in FY2016. 8 of 22 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026-H1.
Immuno-Biological Laboratories moved to the "Worse" side of this theme in 2023, 1 year before the typical company in this theme (2024).
20 other companies' latest entry also says "Other".
- FY2026-H1Continued repayment of long-term borrowingsAnnual report
「Funds used in financing activities amounted to ¥14.568 million, compared with ¥38.857 million used in the same period of the previous year. This was mainly due to ¥14.568 million in repayments of long-term borrowings, among other factors.」
The Company repaid ¥14.568 million in long-term borrowings rather than raising new equity or debt. Cash used in financing activities declined from ¥38.857 million in the same period of the previous year. - FY2025RestatedAnnual report
「The Company generally finances its needs with internal funds, but also considers bank borrowings and equity financing through new share issues, depending on circumstances.」
The Company continues to base its funding policy on internal funds while considering borrowings and equity financing as needed. During the period, it borrowed ¥20 million in long-term debt and repaid ¥52.003 million, resulting in ¥31.755 million of cash used in financing activities. - FY2025-H1Continued repayment of long-term borrowingsAnnual report
「Funds used in financing activities amounted to ¥38.857 million, compared with ¥2.996 million provided in the same period of the previous year. This was mainly due to ¥41.667 million in repayments of long-term borrowings, among other factors.」
Rather than raising new equity or debt, the Company repaid ¥41.667 million in long-term borrowings, resulting in ¥38.857 million of cash used in financing activities. Borrowing repayments continued. - FY2024ReframedAnnual report
「The Company generally finances its needs with internal funds, but also considers bank borrowings and equity financing through new share issues, depending on circumstances.」
The funding policy shifted from the previous emphasis on external financing to one based on internal funds, with borrowings and equity financing considered as needed. - FY2023-Q3ReframedAnnual report
「The ¥350 million allocated to R&D funding for preclinical and clinical trials aimed at out-licensing anti-HIV antibodies, with a planned spending period from April 2020 to March 2023, is no longer required. However, to maintain a stable financial position and enhance corporate value, approximately ¥350 million will be required for the development of in-vitro diagnostic products and their raw materials, with a planned spending period from April 2023 to March 2025. The change was therefore made.」
The planned use of funds was changed from ¥350 million for R&D on anti-HIV antibodies to approximately ¥350 million for the development of in-vitro diagnostic products and raw materials from April 2023 to March 2025. - FY2023-Q2Borrowing-based financing was limited in scale.Annual report
「Funds provided by financing activities amounted to ¥2.995 million, compared with ¥132 million provided in the same period of the previous year. This was mainly due to a net increase of ¥5 million in short-term borrowings, among other factors.」
Although short-term borrowings increased by ¥5 million, ¥2.004 million in long-term borrowings was repaid, resulting in ¥2.995 million in cash provided by financing activities. The scale of external financing declined from ¥132 million in the same period of the previous year. - FY2022-Q3Change in use of funds following the expiration of stock acquisition rights and new borrowingsAnnual report
「The exercise period for the stock acquisition rights expired on 19 December 2021, leaving ¥454 million unexercised. Accordingly, the planned use of funds for ¥150 million in joint research toward the commercialization of artificial feed has been suspended for the time being, while the ¥350 million in R&D funding for preclinical and clinical trials aimed at out-licensing anti-HIV antibodies will be used by CURED, an equity-method affiliate of the Company.」
In response to ¥454 million in unexercised stock acquisition rights, the planned use of funds was changed: the joint research funding for artificial feed was suspended for the time being, while the R&D funding for anti-HIV antibodies will be used by CURED. Total planned uses of funds decreased from ¥2,100 million to ¥1,600 million after the change. Short- and long-term borrowings also increased, including ¥165 million in new borrowings. - FY2022-Q2AdvancedAnnual report
「This was mainly due to a net increase of ¥100.000 million in short-term borrowings and proceeds of ¥40.000 million from long-term borrowings, among other factors.」
A net increase of ¥100.000 million in short-term borrowings and ¥40.000 million in long-term borrowings resulted in cash provided by financing activities of ¥132.000 million. The company resumed raising funds through external borrowings. - FY2022-Q1RestatedAnnual report
「This was mainly due to the repayment of ¥6.500 million in long-term borrowings, including long-term borrowings due for repayment within 1 year, and a ¥6.074 million decrease in other current liabilities resulting from payments of corporate income taxes and other taxes, among other factors.」
The company continued to repay ¥6.500 million in long-term borrowings rather than raise new equity or debt financing. - FY2021Convertible bond redemption and debt repayments carried outAnnual report
「Cash used in financing activities was ¥216.000 million, compared with cash provided of ¥81.195 million in the previous year. This was mainly due to cash inflows of ¥50.000 million from long-term borrowings, offset by cash outflows of ¥66.000 million for repayments of long-term borrowings and ¥200.000 million for the redemption of convertible bond-type bonds with stock acquisition rights.」
While obtaining ¥50.000 million in new borrowings, the company repaid ¥66.000 million in long-term borrowings and redeemed ¥200.000 million in convertible bond-type bonds with stock acquisition rights, resulting in a net cash outflow from external financing. - FY2021-Q3Continuing to repay long-term borrowingsAnnual report
「The decrease in cash and deposits was attributable to factors including the recording of a quarterly net loss attributable to owners of the parent and repayments of borrowings, despite increases resulting from tax refunds and progress in collecting accounts receivable.」
Cash and deposits decreased by ¥263.778 million, and the company repaid ¥49.500 million in long-term borrowings. Funding management involving debt repayments, rather than new financing, continued. - FY2021-Q2Net repayments despite new borrowingsAnnual report
「Proceeds from long-term borrowings ¥10.000 million」
While obtaining ¥10.000 million in long-term borrowings, the company repaid ¥33.000 million in long-term borrowings, resulting in a ¥23.000 million cash outflow from financing activities. - FY2020AdvancedAnnual report
「The company raised ¥467.855 million in proceeds from the issuance of shares upon the exercise of stock acquisition rights.」
The company raised ¥467.855 million through the exercise of stock acquisition rights and continued to secure external funding to support research and development, facility improvements and other purposes. - FY2019AdvancedAnnual report
「Capital increases through the exercise of stock acquisition rights were also carried out during the consolidated fiscal year.」
The exercise of stock acquisition rights attached to convertible bond-type bonds resulted in the issuance of 391,500 shares and increases of ¥156.208 million each in capital and capital surplus. The company continued to raise external funds for research and development and joint research investments. - FY2019-Q1AdvancedAnnual report
「During the cumulative first quarter, the number of shares increased by 87,000 as a result of the exercise of stock acquisition rights attached to the Series 2 unsecured convertible bond-type bonds with stock acquisition rights. As a result, during the cumulative first quarter, capital and capital surplus each increased by ¥34.713 million. At the end of the first-quarter consolidated accounting period, capital was ¥2,671.015 million and capital surplus was ¥1,703.395 million.」
The exercise of stock acquisition rights attached to convertible bond-type bonds resulted in the issuance of 87,000 shares and increases of ¥34.713 million each in capital and capital surplus. - FY2018AdvancedAnnual report
「1 April 2017–31 March 2018 913,500 8,333,090 364,486 2,636,302 364,486 1,668,682」
The exercise of stock acquisition rights attached to convertible bond-type bonds resulted in the issuance of 913,500 shares and increases of ¥364.486 million each in capital and capital surplus. - FY2018-Q3AdvancedAnnual report
「After the end of the third-quarter consolidated accounting period and by 14 February 2018, some of the Series 2 unsecured convertible bond-type bonds with stock acquisition rights were exercised as follows. 1. Face value of bonds exercised: ¥104.139 million 2. Number of stock acquisition rights exercised: 3 3. Class and number of shares issued: common shares, 130,500 shares 4. Increase in capital: ¥52.069 million 5. Increase in capital surplus: ¥52.069 million」
Some of the Series 2 unsecured convertible bond-type bonds with stock acquisition rights were exercised, resulting in the issuance of 130,500 shares and increases of ¥52.069 million each in capital and capital surplus. - FY2017RestatedAnnual report
「The group is raising funds for capital investment and other purposes in the genetically modified silkworm business through the exercise of stock acquisition rights and the issuance of convertible bond-type bonds with stock acquisition rights, among other means.」
The company raised funds through the exercise of stock acquisition rights of ¥574.716 million, the issuance of convertible bond-type bonds with stock acquisition rights of ¥1,381.395 million, and long-term borrowings of ¥330.000 million, among other means. - FY2017-Q3AdvancedAnnual report
「During the third-quarter consolidated accounting period, the company raised funds through an allocation to With Partners Co., Ltd. This funding was intended not only to secure funds but also to expand the genetically modified silkworm business and accelerate research and development by leveraging the company's domestic and overseas network.」
The company raised funds through an allocation to With Partners and is seeking to expand the genetically modified silkworm business and accelerate research and development by leveraging its domestic and overseas network. The financial position also reflects the issuance of bonds of ¥1,388.520 million and a ¥228.434 million increase in borrowings from new loans. - FY2017-Q2RestatedAnnual report
「This was mainly due to proceeds of ¥545.847 million from the issuance of shares upon the exercise of stock acquisition rights and a ¥330.000 million increase in long-term borrowings from new bank loans, among other factors.」
The company raised ¥545.847 million through the exercise of stock acquisition rights and obtained ¥330.000 million in new bank loans, securing external funding for research and development, capital investment and other purposes. - FY2017-Q1AdvancedAnnual report
「During the cumulative first quarter, the company issued new shares upon the exercise of stock acquisition rights.」
The exercise of stock acquisition rights resulted in the issuance of 540,000 shares and raised ¥548.230 million. The company also obtained new loans from financial institutions, increasing cash and deposits by ¥711.590 million. - FY2016First statedAnnual report
「Although we believe it is desirable for investments to be funded from business earnings, when a research and development project is expected to require substantial upfront investment, we will raise funds through share issuances and other means.」
The policy is to raise funds through share issuances and other means when research and development projects require substantial upfront investment. In practice, the company has carried out third-party allotments and issued bonds.